Loading clinical trials...

Early Detection of PDAC in Patients With Chronic Pancreatitis | Clinical Trials | Clareo Health

COMPLETED

Early Detection of PDAC in Patients With Chronic Pancreatitis

High Efficiency of Early Detection of Synchronous Pancreatic Ductal Adenocarcinoma in Patients With Chronic Pancreatitis

NCT07104864•First Affiliated Hospital Xi'an Jiaotong University

View on ClinicalTrials.gov

Summary

The goal of this study is to find simple warning signs that doctors can use to spot pancreatic cancer early in people who have chronic pancreatitis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. a confirmed diagnosis of chronic pancreatitis; (2) availability of pathological confirmation.

Exclusion Criteria

•1. age less than 18 years; (2) ambiguous pathology, including cases with only cytological findings or indications of pancreatic tissue alone; (3) preoperative diagnosis of PDAC or other pancreatic tumors before invasive procedure; (4) presence of tumors in other organs; (5) patients with missing data exceeding 15% of the total dataset.

Locations (1)

the First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Key Dates

Start Date

August 1, 2024

Primary Completion Date

December 1, 2024

Completion Date

December 1, 2024

Last Updated

August 5, 2025

Enrollment

359

ACTUAL participants

Conditions

Chronic PancreatitisPDAC - Pancreatic Ductal Adenocarcinoma

Interventions

histopathological confirmation

DIAGNOSTIC_TEST

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

NCT04900818

Solid TumorAdvanced Cancer+6 more

View study

RECRUITINGPHASE1/PHASE2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591

PDACPDAC - Pancreatic Ductal Adenocarcinoma+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Early Detection of PDAC in Patients With Chronic Pancreatitis

Inclusion Criteria

Exclusion Criteria

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

Scrambler Therapy in Chronic Pancreatitis

Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA)